We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Aggrenox MDL Nears End As Drug Cos. Reach Final Deal

Law360 (June 11, 2018, 8:02 PM EDT) -- Teva Pharmaceutical and Boehringer Ingelheim on Monday announced a settlement with the last remaining party accusing them of entering into an illegal pay-for-delay agreement to keep a generic version of the stroke prevention medicine Aggrenox off the market, paving the way for the multidistrict litigation in Connecticut federal court to close out.

The confidential deal with Blue Cross and Blue Shield of Louisiana comes days after the court dismissed fellow insurer Humana Inc.’s claims against the drugmakers as part of another settlement, and as the court awaits...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.